2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid; 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-acetic Acid; [4-[(5,6-Diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic Acid; 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]acetic Acid; ACT 333679; [4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]acetic Acid
MRE-269 (ACT-333679) is a fully characterized chemical compound used as a reference standard of API Selexipag. The standard offered is compliant with regulatory guidelines. MRE-269 (ACT-333679) is used for analytical method development, method validation (AMV), and Quality Controlled (QC) applications during synthesis and formulation stages of drug development and serves as a reference standard for traceability against pharmacopeial standards (USP or EP). Axios Research products are intended for analytical purposes only and are not for human use. CAS - 475085-57-5
Related products
MRE-269-d6 (ACT-333679-d6)
M.F. C₂₅H₂₃D₆N₃O₃
M.W. 425.56
CAT# AR-S01244
CAS# 475085-57-5 (non-labelled)
